The European Commission fined Teva Pharmaceuticals Industries €462.6m for anti-competitive practices related to multiple sclerosis treatment Copaxone. Teva extended patent protection, disseminated misleading information, and disparaged competitors to block market entry, violating EU regulations. Teva plans to appeal the decision.